Clinical Peptide Medicine — Structured. Applied. Evolving.
B7-33 Peptide Guide: Understanding Antifibrotic Signaling and RXFP1
B7-33 is a single-chain peptide derived from the B-chain of human relaxin-2 and designed to preserve important antifibrotic actions of relaxin while simplifying the parent hormone's structure.
That immediately makes B7-33 interesting.
Human relaxin-2 is not a small, simple peptide.
It is a:
- TWO-CHAIN PEPTIDE HORMONE
with:
- THREE DISULFIDE BONDS.
Its biological effects include:
- vasodilation
- extracellular-matrix remodeling
- antifibrotic signaling
- cardiovascular adaptation
- renal effects
- vascular biology
- connective-tissue remodeling
But the native relaxin molecule is structurally complex and can be difficult to reproduce as a simple therapeutic scaffold.
B7-33 was developed as a much smaller:
- SINGLE-CHAIN RELAXIN-DERIVED AGONIST.
Its central target is:
- RELAXIN FAMILY PEPTIDE RECEPTOR 1 — RXFP1.
What makes B7-33 especially compelling is that it appears to behave as a:
- FUNCTIONALLY SELECTIVE AGONIST.
That means it does not necessarily reproduce every signal generated by full-length relaxin.
Instead, it may preferentially activate:
- THE SIGNALING PROGRAMS MOST RELEVANT TO ANTIFIBROTIC AND MATRIX-REMODELING EFFECTS.
That is a major concept.
The best way to understand B7-33 is not:
- “A SHORTER VERSION OF RELAXIN.”
A better description is:
- A FUNCTIONALLY SELECTIVE RXFP1 AGONIST ENGINEERED TO RETAIN RELAXIN-LIKE ANTIFIBROTIC BIOLOGY WITH A SIMPLER SINGLE-CHAIN STRUCTURE.
Preclinical studies have shown that B7-33 can reproduce important relaxin-like antifibrotic effects in fibroblasts and several animal models despite showing weaker activity in some artificial receptor-expression systems.
THE CORE MECHANISM MAP
B7-33
↓
RXFP1
Potential crosstalk with:
AT2R
↓
Preferential:
ERK1/2
↓
MMP-2 ↑
↓
EXTRACELLULAR-MATRIX DEGRADATION / REMODELING
↓
Potential:
FIBROSIS ↓
↓
Potential improvement in:
TISSUE COMPLIANCE + ORGAN FUNCTION
The key idea is:
- B7-33 DOES NOT SIMPLY BLOCK COLLAGEN PRODUCTION.
It may help shift the tissue back toward:
- NORMAL MATRIX TURNOVER.
WHAT THIS MECHANISM MAY SUGGEST
Mechanistically, B7-33 deserves research interest in:
- cardiac fibrosis
- pulmonary fibrosis
- renal fibrosis
- airway remodeling
- chronic inflammatory tissue remodeling
- post-injury fibrosis
- pathological scarring
- selected vascular-remodeling conditions
The common denominator is not:
- THE ORGAN.
It is:
- EXCESSIVE EXTRACELLULAR-MATRIX ACCUMULATION.
WHAT THIS MECHANISM DOES NOT PROVE
B7-33 biology does not prove that it:
- reverses every fibrotic disease
- removes mature scar tissue completely
- treats every form of heart failure
- treats every pulmonary disease
- reverses advanced cirrhosis
- restores organs destroyed by end-stage fibrosis
- should be used whenever collagen is elevated
- is appropriate for every wound
Again:
- FIBROSIS IS A FINAL COMMON PATHWAY.
But the drivers can be:
- autoimmune
- infectious
- toxic
- metabolic
- ischemic
- mechanical
- genetic
Same fibrosis.
Different:
- CAUSE.
PRECLINICAL EVIDENCE
B7-33 is derived from the B-chain of human relaxin-2, which is part of the broader insulin/relaxin peptide superfamily. This parent hormone comprises an A-chain and a B-chain linked by disulfide bonds. Researchers have identified that many of the key residues crucial for interaction with RXFP1, a receptor involved in antifibrotic therapy, are located in the B-chain. This discovery led to a significant question: could the biologically important components of relaxin be condensed into one soluble linear peptide? B7-33 emerged as one answer to that question, as it was produced by modifying the relaxin B-chain to enhance solubility while maintaining vital receptor interactions for effective peptide medicine. Subsequent research continues to focus on refining this minimal relaxin scaffold for improved applications in combating fibrosis and enhancing RXFP1 signaling.
HUMAN THERAPEUTIC EVIDENCE
HUMAN RELAXIN-2
↓
Two-chain hormone
↓
Important RXFP1-binding information concentrated in:
B-CHAIN
↓
Peptide minimization leads to the development of B7-33, a SINGLE-CHAIN RXFP1 AGONIST.
↓
This compound induces preferential signaling involving:
ERK1/2
MMP-2
MATRIX REMODELING
↓
The potential applications include promising ANTIFIBROTIC EFFECTS, making it a key player in antifibrotic therapy for conditions related to fibrosis.
Again:
the key concept is not simply:
SHORTER PEPTIDE.
It is:
SELECTIVE PRESERVATION OF THE DESIRED BIOLOGICAL MESSAGE using advances in peptide medicine.
DO NOT BEGIN WITH B7-33
Begin with: WHY IS THIS TISSUE BECOMING FIBROTIC?
Then:
PHYSIOLOGY
↓
PATTERN
↓
MECHANISM
↓
EVIDENCE
↓
RISK
↓
MONITORING
↓
DECISION
PHYSIOLOGY
Normal tissue repair requires:
- fibroblast activation
- matrix deposition
- collagen
- wound closure
- matrix degradation
- remodeling
- resolution
Again:
fibrosis begins with:
- NORMAL REPAIR BIOLOGY.
The problem is:
- FAILURE TO RESOLVE.
EVIDENCE
Ask:
- WHAT EVIDENCE EXISTS FOR B7-33 IN THIS ORGAN AND THIS TYPE OF FIBROSIS?
- Heart?
- Lung?
- Kidney?
- Scar?
Again:
- fibrosis is a common mechanism.
But organs differ in:
- matrix composition
- receptor expression
- vascular environment
- reversibility
PATTERN
What is actually happening?
- early fibrosis?
- active inflammation?
- mature scar?
- ongoing toxic injury?
- post-infarction remodeling?
- renal fibrosis?
- pulmonary fibrosis?
- hypertrophic scar?
- normal healing?
Again:
- “COLLAGEN IS PRESENT”
does not equal:
- PATHOLOGICAL FIBROSIS.
RISK
Potential considerations include:
- excessive matrix breakdown
- altered vascular signaling
- blood-pressure effects depending on biology and formulation
- interactions with cardiovascular therapy
- insufficient exposure
- product-quality issues
- mistaking irreversible structural loss for reversible fibrosis
- delaying treatment of the primary disease
Again:
the central problem may not be:
- THE SCAR.
It may be:
- WHAT KEEPS CREATING THE SCAR.
MECHANISM
Does B7-33 biology match:
- THE DOMINANT BOTTLENECK?
If fibrosis is being driven by:
- UNCONTROLLED HEPATITIS,
control the:
- LIVER INJURY.
If cardiac fibrosis is being driven by:
- SEVERE UNTREATED HYPERTENSION,
address:
- AFTERLOAD.
If pulmonary fibrosis follows:
- ONGOING TOXIC EXPOSURE,
remove:
- THE EXPOSURE.
Antifibrotic signaling becomes much more compelling when:
- THE DRIVER IS CONTROLLED BUT MALADAPTIVE MATRIX REMODELING CONTINUES.
MONITORING
Monitoring should follow:
THE ORGAN + THE FIBROTIC PROCESS.
CARDIAC
Potential measures:
- symptoms
- blood pressure
- echocardiographic parameters
- ventricular function
- functional capacity
- cardiac MRI where appropriate
- fibrosis-related imaging or biomarkers
PULMONARY
- symptoms
- pulmonary function
- diffusion capacity
- exercise tolerance
- imaging
RENAL
- creatinine / eGFR
- albuminuria / proteinuria
- blood pressure
- disease-specific markers
- imaging where appropriate
STRUCTURAL FIBROSIS
Where available:
- imaging
- elastography
- histology
- functional organ measurements
Again:
if the hypothesis is:
- FIBROSIS IS BEING REVERSED,
monitor something that reflects:
- FIBROSIS OR FUNCTION.
THE PRAXIS 5
MECHANISM
B7-33 is derived from the B-chain of human relaxin-2, which is part of the broader insulin/relaxin peptide superfamily. This parent hormone comprises an A-chain and a B-chain linked by disulfide bonds. Researchers have identified that many of the key residues crucial for interaction with RXFP1, a receptor involved in antifibrotic therapy, are located in the B-chain. This discovery led to a significant question: could the biologically important components of relaxin be condensed into one soluble linear peptide? B7-33 emerged as one answer to that question, as it was produced by modifying the relaxin B-chain to enhance solubility while maintaining vital receptor interactions for effective peptide medicine. Subsequent research continues to focus on refining this minimal relaxin scaffold for improved applications in combating fibrosis and enhancing RXFP1 signaling.
EVIDENCE
HUMAN RELAXIN-2
↓
Two-chain hormone
↓
Important RXFP1-binding information concentrated in:
B-CHAIN
↓
Peptide minimization leads to the development of B7-33, a SINGLE-CHAIN RXFP1 AGONIST.
↓
This compound induces preferential signaling involving:
ERK1/2
MMP-2
MATRIX REMODELING
↓
The potential applications include promising ANTIFIBROTIC EFFECTS, making it a key player in antifibrotic therapy for conditions related to fibrosis.
Again:
the key concept is not simply:
SHORTER PEPTIDE.
It is:
SELECTIVE PRESERVATION OF THE DESIRED BIOLOGICAL MESSAGE using advances in peptide medicine.
RISK
No. It is: RELAXIN-DERIVED. But not: PHARMACOLOGICALLY IDENTICAL. This distinction is important in the context of antifibrotic therapy. Full relaxin activates RXFP1 through multiple signaling pathways, which are crucial for addressing fibrosis. B7-33, a peptide medicine, appears to favor some pathways more strongly than others. That is called: FUNCTIONAL SELECTIVITY or: BIASED AGONISM.
MONITORING
A receptor does not always behave like ON or OFF. One receptor can activate various pathways including cAMP, ERK, nitric oxide, kinase pathways, transcriptional responses, and matrix-remodeling programs. Different ligands can push the same receptor toward different downstream signals. Thus, the same receptor does not always correspond to the same biological response, a crucial concept in modern pharmacology. B7-33 serves as an illustrative example, showing relatively modest cAMP signaling in some systems while also maintaining potent antifibrotic signaling in fibroblasts through RXFP1 signaling involving pERK1/2 and MMP-2. This makes it a significant consideration in antifibrotic therapy and peptide medicine targeting fibrosis.
PATIENT CONTEXT
RXFP1
↓
Can produce multiple intracellular signals, making it a key player in antifibrotic therapy.
Full relaxin:
BROAD SIGNALING PROFILE
B7-33:
SELECTIVE SIGNALING PROFILE
↓
Preferential:
ERK1/2
↓
MMP-2
↓
Potential:
COLLAGEN DEGRADATION + MATRIX REMODELING, crucial in tackling fibrosis.
Again:
the therapeutic idea is:
KEEP THE SIGNAL YOU WANT
while reducing:
UNNECESSARY SIGNALING ELSEWHERE. This approach emphasizes the significance of RXFP1 signaling and its role in peptide medicine.
SEVEN QUESTIONS TO ASK BEFORE B7-33
1. WHAT FIBROTIC PROCESS ARE WE ACTUALLY TRYING TO CHANGE?
cardiac?
pulmonary?
renal?
scar?
something else?
2. WHAT IS DRIVING THE FIBROSIS?
inflammation?
pressure overload?
toxin?
infection?
ischemia?
autoimmunity?
mechanical injury?
3. IS THE DRIVER STILL ACTIVE?
If yes:
addressing the fibrosis with antifibrotic therapy without managing the underlying driver may create:
A LOSING FEEDBACK LOOP.
4. DOES B7-33'S RXFP1 SIGNALING AND MATRIX-REMODELING MECHANISM MATCH THIS TISSUE?
functional RXFP1?
fibroblast-driven matrix accumulation?
potentially reversible fibrosis?
5. WHAT TYPE OF EVIDENCE SUPPORTS THIS APPLICATION OF PEPTIDE MEDICINE?
cellular?
animal?
organ-specific?
human translational?
6. WHAT WILL WE MONITOR?
structure?
organ function?
symptoms?
fibrosis markers?
blood pressure?
imaging?
7. WHAT WOULD DEFINE SUCCESS?
Not:
“COLLAGEN WENT DOWN.”
But:
PATHOLOGICAL MATRIX REMODELING IMPROVED, WHILE THE ORGAN BECAME MORE FUNCTIONAL.
B7-33
KEY TAKEAWAYS
1. WHAT FIBROTIC PROCESS ARE WE ACTUALLY TRYING TO CHANGE?
cardiac?
pulmonary?
renal?
scar?
something else?
2. WHAT IS DRIVING THE FIBROSIS?
inflammation?
pressure overload?
toxin?
infection?
ischemia?
autoimmunity?
mechanical injury?
3. IS THE DRIVER STILL ACTIVE?
If yes:
addressing the fibrosis with antifibrotic therapy without managing the underlying driver may create:
A LOSING FEEDBACK LOOP.
4. DOES B7-33'S RXFP1 SIGNALING AND MATRIX-REMODELING MECHANISM MATCH THIS TISSUE?
functional RXFP1?
fibroblast-driven matrix accumulation?
potentially reversible fibrosis?
5. WHAT TYPE OF EVIDENCE SUPPORTS THIS APPLICATION OF PEPTIDE MEDICINE?
cellular?
animal?
organ-specific?
human translational?
6. WHAT WILL WE MONITOR?
structure?
organ function?
symptoms?
fibrosis markers?
blood pressure?
imaging?
7. WHAT WOULD DEFINE SUCCESS?
Not:
“COLLAGEN WENT DOWN.”
But:
PATHOLOGICAL MATRIX REMODELING IMPROVED, WHILE THE ORGAN BECAME MORE FUNCTIONAL.
THE BOTTOM LINE
B7-33 is a particularly valuable peptide for understanding:
- MODERN RECEPTOR PHARMACOLOGY.
The old model says:
PEPTIDE
↓
RECEPTOR
↓
RESPONSE
But biology is more complex.
A better model is:
PEPTIDE
↓
RECEPTOR
↓
MULTIPLE POSSIBLE SIGNALING PATHWAYS
↓
Different biological outcomes.
And then:
- A DIFFERENT PEPTIDE
can bind the same receptor and preferentially select:
- A DIFFERENT SIGNAL.
That is:
- BIASED AGONISM.
B7-33 was designed around exactly that principle.
Instead of reproducing all of human relaxin researchers reduced the molecule to:
- A SINGLE-CHAIN PEPTIDE
that retains important:
- RXFP1-MEDIATED ANTIFIBROTIC SIGNALING.
Its most compelling pathway looks something like:
B7-33
↓
RXFP1 / AT2R
↓
ERK1/2
↓
MMP-2
↓
EXTRACELLULAR-MATRIX REMODELING
↓
Potential:
FIBROSIS REVERSAL
That has major implications because fibrosis is one of the final common pathways of:
- CHRONIC ORGAN INJURY.
- Heart disease.
- Kidney disease.
- Lung disease.
- Chronic inflammation.
All can ultimately converge on:
- MATRIX ACCUMULATION.
But fibrosis itself is not:
- THE WHOLE DISEASE.
It is often:
- THE FOOTPRINT LEFT BY THE DISEASE.
So the Praxis question should never simply be:
- “HOW DO WE BREAK DOWN THE SCAR?”
It should be:
- “WHY IS THIS TISSUE STILL BEING TOLD TO SCAR?”
Then:
- “HAS THE DRIVER BEEN CONTROLLED?”
Then:
- “IS THE MATRIX STILL BIOLOGICALLY REVERSIBLE?”
And only then:
- “DOES RXFP1-BIASED SIGNALING OFFER A MECHANISTICALLY COHERENT WAY TO SHIFT THE tissue from continued deposition back toward organized remodeling, and what objective measure would prove that the organ—not merely a biomarker—actually became healthier?”
That is the difference between:
- ATTACKING COLLAGEN
and:
- UNDERSTANDING FIBROSIS.
STOP MEMORIZING PEPTIDES. START UNDERSTANDING THE SYSTEM.